**【 研 究 業 績 】**

**＜発表論文＞**

原著

（研究室主体）

1. Takeuchi S, Yanagitani N, Seto T, Hattori Y, Ohashi K, Morise M, Matsumoto S, Yoh K, Goto K, Nishio M, Takahara S, Kawakami T, Imai Y, Yoshimura K, Tanimoto A, Nishiyama A, Murayama T, Yano S. Phase I/II study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET). **Transl Lung Cancer Res** 2021, 10(1):314-25. doi: 10.21037/tlcr-20-549.
2. Fukuda K, Otani S, Takeuchi S, Arai S, Nanjo S, Tanimoto A, Nishiyama A, Naoki K, Yano S. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer. **Cancer Sci** 2021 Sep; 112(9): 3784-95. doi: 10.1111/cas.15035.
3. Sato S, Tanimoto A, Yanagimura N, Suzuki C, Takumi Y, Nishiyama A, Yamashita K, Takeuchi S, Ohtsubo K, Makino T, Yoshida Y, Hirono Y, Hayashi R, Koizumi T, Nakazawa Y, Ito KI, Motoo Y, Uramoto H, Nakada M, Nishino Y, Yano S. Multi-institutional survey of cancer disparities in disabled patients in the region of northwestern Japan. **Int J Clin Oncol** 2021 (6):1009-14.
4. Tanimoto A, Matsumoto S, Takeuchi S, Arai S, Fukuda K, Nishiyama A, Goto K, Yano S. Proteasome inhibition overcomes ALK-TKI resistance by p53 inactivation through Noxa expression in *ALK*-rearranged NSCLC. **Clin Cancer Res** 2021, 27(5):1410-20. doi: 10.1158/1078-0432.CCR-20-2853.
5. Nishiyama A, Hattori Y, Takeuchi S, Tanimoto A, Satouchi M, Murayama T, Yano S. Severe skin toxicity caused by sequential anti-PD-1 antibody and alectinib in non-small-cell lung cancer: a report of two cases and a literature review. **Intern Med** 2021 Nov 20.doi: 10.2169/internalmedicine.7472-21. Online ahead of print.
6. Suzuki C, Kiyota N, Imamura Y, Goto H, Suto H, Chayahara N, Toyoda M, Ito Y, Miya A, Miyauchi A, Teshima M, Otsuki N, Nibu KI, Minami H. Exploratory analysis to predict optimal tumor burden for starting lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. **Front Oncol** 2021 Jul 8;11:638123. doi: 10.3389/fonc.2021.638123.
7. Sakaguchi H, Tanimoto A, Sato S, Yanagimura N, Suzuki C, Takumi Y, Nishiyama A, Yamashita K, Takeuchi S, Ohtsubo K, Yano S. Mediastinal malignant melanoma markedly shrinking in response to nivolumab. **Intern Med** 2021 Jun 26. doi: 10.2169/internalmedicine.7452-21.
8. Ohtsubo K, Yamashita K, Yanagimura N, Suzuki C, Tanimoto A, Nishiyama A, Takeuchi S, Iwaki N, Kawano M, Izumozaki A, Inoue D, Gabata T, Ikeda H, Watanabe M, Yano S. Multiple malignant lymphomas of the bile duct developing after spontaneous regression of an autoimmune pancreatitis-like mass.  **Int Med,** 2021 Feb 1; 60(3): 409-15. doi: 10.2169/internalmedicine.5429-20.
9. Nishiyama A, Staub Y, Suga Y, Fujita M, Tanimoto A, Ohtsubo K, Yano S. Sarcopenia may influence the prognosis in advanced thyroid cancer patients treated with molecular targeted therapy. **In Vivo** 2021;35(1):401-10. doi: 10.21873/invivo.12271.
10. Sakaguchi H, Tanimoto A, Sato S, Yanagimura N, Suzuki C, Takumi Y, Nishiyama A, Yamashita K, Takeuchi S, Ohtsubo K, Yano S. Clinical outcome of inoperable pancreatic cancer pTreated with FOLFIRINOX or gplus nab-paclitaxel as a first-line therapy: a retrospective analysis. **Medicine International** 2021, doi: org/10.3892/mi.2021.8.
11. Wang M, Han X, Liu C, Takayama R, Yasugi T, Ei SI, Nagayama M, Tanaka Y, Sato M. Intracellular trafficking of Notch orchestrates temporal dynamics of Notch activity in the fly brain. **Nat Commun** 2021 Apr 7;12(1):2083. doi: 10.1038/s41467-021-22442-3.

（共同研究）

1. Uramoto H, Takiguchi T, Koizumi T, Tanimoto A, Hayashi R, Nakazawa Y, Ito KI, Nakada M, Hirono Y, Nishino Y, Yano S. Multi-institutional survey of thymic carcinoma patients in Hokushin region. **J Cancer Res Clin Oncol** 2021 May 8. doi: 10.1007/s00432-021-03620-8. Online ahead of print.
2. Uramoto H, Takiguchi T, Koizumi T, Tanimoto A, Hayashi R, Nakazawa Y, Ito KI, Nakada M, Hirono Y, Nishino Y, Yano S. Multi-institutional survey of malignant pleural mesothelioma patients in the Hokushin region. **J Cancer Res Clin Oncol** 2021 Jun 29. doi: 10.1007/s00432-021-03699-z. Online ahead of print.
3. Nakasuka F, Tabata S, Sakamoto T, Hirayama A, Ebi H, Yamada T, Umetsu K, Ohishi M, Ueno A, Goto H, Sugimoto M, Nishioka Y, Yamada Y, Tomita M, Sasaki AT, Yano S, Soga T. TGF-β-dependent reprogramming of amino acid metabolism induces epithelial-mesenchymal transition in non-small cell lung cancers. **Commun Biol** 2021 Jun 24;4(1):782. doi: 10.1038/s42003-021-02323-7.
4. Sheng J, Kohno S, Okada N, Okahashi N, Teranishi K, Matsuda F, Shimizu H, Linn P, Nagatani N, Yamamura M, Harada K, Horike SI, Inoue H, Yano S, Kumar S, Kitajima S, Ajioka I, Takahashi C. Treatment of retinoblastoma 1-intact hepatocellular carcinoma with cyclin-dependent kinase 4/6 inhibitor combination therapy. **Hepatology** 2021 Oct;74(4):1971-93. doi: 10.1002/hep.31872. Epub 2021 Aug 25.
5. Okura E, Nishino Y, Sakashita K, Tanimoto A, Hayashi R, Yoshida Y, Nakada M, Koizumi T, Yano S, Nakazawa Y. Cancer among children, adolescents and young adults in the Hokushin region, Japan, between 2010 and 2015. **Jpn J Clin Oncol** 2021 Nov 16;hyab174. doi: 10.1093/jjco/hyab174. Online ahead of print.
6. Goto S, Sakoda Y, Adachi K, Sekido Y, Yano S, Eto M, Tamada K. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models. **Cancer Immunol Immunother** 2021 Sep;70(9):2503-15. doi: 10.1007/s00262-021-02853-3. Epub 2021 Feb 8.
7. Yoshimura A, Yamada T, Okuma Y, Fukuda A, Watanabe S, Nishioka N, Takeda T, Chihara Y, Takemoto S, Harada T, Hiranuma O, Shirai Y, Nishiyama A, Yano S, Goto Y, Shiotsu S, Kunimasa K, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Kenmotsu H, Takahashi T, Takayama K. Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. **Transl Lung Cancer Res** 2021 Aug;10(8):3582-93.doi: 10.21037/tlcr-21-461.
8. Tanimura K, Yamada T, Horinaka M, Katayama Y, Fukui S, Morimoto K, Nakano T, Tokuda S, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Yoneda K, Yano S, Sakai T, Takayama K. Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer. **Cancer Lett** 2021 Dec 1;522:119-28. doi: 10.1016/j.canlet.2021.09.018. Epub 2021 Sep 15.
9. Yasuda H, Ichihara E, Sakakibara-Konishi J, Zenke Y, Takeuchi S, Morise M, Hotta K, Sato M, Matsumoto S, Tanimoto A, Matsuzawa R, Kiura K, Takashima Y, Yano S, Koyama J, Fukushima T, Hamamoto J, Terai H, Ikemura S, Takemura R, Goto K, Soejima K. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. **Lung Cancer**. 2021 Oct 16;162:140-6. doi: 10.1016/j.lungcan.2021.10.006. Online ahead of print.
10. Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K, Cervantes EV, Bulliard Y, Tu N, Lee SB, Yu B, Locke FL, Davila ML. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. **J Immunother Cancer** 2021 ;(10):e003354. doi: 10.1136/jitc-2021-003354.
11. Izumi K, Iwamoto H, Yaegashi H, Nohara T, Shigehara K, Kadono Y, Nanjo S, Yamada T, Ohtsubo K, Yano S, Mizokami A. Androgen replacement therapy for cancer-related symptoms in male: result of prospective randomized trial (ARTFORM study). **J Cachexia Sarcopenia Muscle** 2021 Aug; 12(4): 831-42. doi: 10.1002/jcsm.12716.
12. Jogo T, Nakamura Y, Shitara K, Bando H, Yasui H, Esaki T, Terazawa T, Satoh T, Shinozaki E, Nishina T, Sunakawa Y, Komatsu Y, Hara H, Oki E, Matsuhashi N, Ohta T, Kato T, Ohtsubo K, Kawakami T, Okano N, Yamamoto Y, Yamada T, Tsuji A, Odegaard JI, Taniguchi H, Doi T, Fujii S, Yoshino T. Circulating tumor DNA analysis detects FGFR2 amplification and concurrent genomic alterations associated with FGFR inhibitor efficacy in advanced gastric cancer. **Clin Cancer Res** 2021; 27 (20): 5619-27.
13. Kanno A, Yasuda I, Irisawa A, Hara K, Ashida R, Iwashita T, Takenaka M, Katanuma A, Takikawa T, Kubota K, Kato H, Nakai Y, Ryozawa S, Kitano M, Isayama H, Kamada H, Okabe Y, Hanada K, Ohtsubo K, Doi S, Hisai H, Shibukawa G, Imazu H, Masamune A. Adverse events of endoscopic ultrasound-guided fine-needle aspiration for histologic diagnosis in Japanese tertiary centers: Multicenter retrospective study. **Dig Endosc** 2021; 33 (7): 1146-57.
14. Kometani M, Yoneda T, Maeda Y, Ohtsubo K, Yamazaki Y, Ikeda H, Mori S, Aono D, Karashima S, Usukura M, Sasano H, Takeda Y. Carcinoma of unknown primary origin with isolated adrenal metastasis: a report of two cases. **Endocr J** 2021; 68 (10): 1209-15.
15. Quinn JJ, Jones MG, Okimoto RA, Nanjo S, Chan MM, Yosef N, Bivona TG, Weissman JS. Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. **Science** 2021 Feb 26; 371(6532): eabc1944. doi: 10.1126/science.abc1944.
16. Boucher JC, Li G, Kotani H, Cabral ML, Morrissey D, Lee SB, Spitler K, Beatty NJ, Cervantes EV, Shrestha B, Yu B, Kazi A, Wang X, Sebti SM, Davila ML. CD28 costimulatory domain-targeted mutations enhance chimeric antigen receptor T-cell function. **Cancer Immunol Res** 2021 Jan;9(1):62-74.
17. Nishikawa Y, Suzuki C, Takahashi Y, Sawano T, Kinoshita H, Clero E, Laurier D, Phan G, Nakayama T, Tsubokura M. No significant association between stable iodine intake and thyroid dysfunction in children after the Fukushima Nuclear Disaster: an observational study. **J Endocrinol Invest** 2021 Jul;　44(7):　1491-500. doi: 10.1007/s40618-020-01454-8.
18. Ogawa S, Shimidzu H, Fukuda K, Tsunekawa N, Hirano T, Sato F, Yura K, Hasunuma T, Ochi K, Yamamoto M, Sakamoto W, Hashimoto K, Ogata H, Kanao T, Nemoto M, Inagaki K, Tamura T.Multiple mutations in RNA polymerase β-subunit gene (rpoB) in Streptomyces incarnatus NRRL8089 enhance production of antiviral antibiotic sinefungin: modeling rif cluster region by density functional theory. **Biosci Biotechnol Biochem** 2021 Apr 24;85(5):1275-82. doi: 10.1093/bbb/zbab011.

著書・総説

1. 矢野聖二.　第3章がん微小環境を標的とした治療薬と耐性. 肺がんの炎症性微小環境および中枢神経系での薬剤耐性.　**実験医学増刊** 39(12):142-6, 2021
2. 矢野聖二.　Special Feature「がんのチロシンキナーゼ阻害薬耐性獲得のメカニズム」**いま知りたい、肺癌診療のすべて PULMOMICS 2021-No**pp.7-10, 2021
3. Nakanuma Y, Uesaka K, Ohtsuka M, Ohtsubo K, Inoue D, Kozaka K. Intraductal Tumors of the Biliary Tract: Precursor Lesions and Variants. Diagnosis and Management of Cholangiocarcinoma-A Multidisciplinary Approach , **Springer**, 27-67, 2021
4. 大坪公士郎,　三宅邦夫,　山下　要,　矢野聖二.　特集 肝胆膵疾患におけるバイオマーカーの意義を探る　膵胆道癌の胆汁メチル化miRNA解析とバイオマーカーとしての意義.　**肝胆膵** 83 (4): 595-601, 2021
5. 西山明宏,　矢野聖二.　がんゲノム医療を検証するPharmacogenomics and iomarker,　NTRK融合遺伝子.　**がん分子標的治療**　19(1): 100-4, 2021
6. 西山明宏.　分子標的薬：小分子化合物　4）TRK阻害薬.　**腫瘍内科** 28(2): 130-4, 2021
7. 小谷　浩.　がん薬物療法専門医のための模擬テスト 137,　**腫瘍内科** 28(2): 213-4, 2021
8. 小谷　浩.　がん薬物療法専門医のための模擬テスト 137―解答と解説―.　**腫瘍内科** 28(3): 324-5, 2021
9. 鈴木千晶,　矢野聖二. 【特集　分子標的薬と耳鼻咽喉科】分子標的薬の耐性化機構.　**JOHNS** 37(12); 1546–50, 2021

**＜学会発表＞**

1. 第51回日本膵臓学会大会　大坪公士郎,　三宅邦夫,　山下　要,　矢野聖二.　膵胆道疾患における血漿中癌抑制型miRNAのメチル化に関する検討.　2021年1月　神戸
2. 第18回日本臨床腫瘍学会　矢野聖二.　［新専門医制度］モデルカリキュラムについて. 2021年2月 Web
3. 第18回日本臨床腫瘍学会　西山明宏.　薬剤の有効性が未確認の変異が検出され分子標的薬が奏効した症例.　2021年2月 Web
4. 第18回日本臨床腫瘍学会　西山明宏.　分子標的薬で治療中の進行甲状腺がんとサルコペニアとの関連.　2021年2月 Web
5. 第18回日本臨床腫瘍学会　Suzuki C, Sakaguchi H, Shimojima M, Yanagimura N, Takumi Y, Tanimoto A, Nishiyama A, Yamashita K, Takeuchi S, Ohtsubo K, Yano S. A case of myocarditis associated with nivolumab/ipilimumab in renal cell carcinoma. 2021年2月 Web
6. 第18回日本臨床腫瘍学会　佐藤成樹,　谷本　梓,　牧野智恵,　吉田好雄,　廣野靖夫,　林 龍二,　小泉知展,　中沢洋三,　伊藤研一,　元雄良治,　浦本秀隆,　中田光俊,　西野善一,　矢野聖二.　Multi-institutional survey of cancer disparities in disabled patients in Hokushin region.　2021年2月 Web
7. 第243回日本内科学会北陸地方会　坂口裕之,　臼倉幹哉,　浅野嵩博,　 朝戸佳世,　杉田光洋,　内田幸助,　若山綾子,　青島敬二,　井野秀一.　水痘・帯状疱疹ウイルスによる無菌性髄膜炎を発症した若年者の一例.　2021年3月Web
8. 第107回日本消化器病学会総会　大坪公士郎,　三宅邦夫,　山下　要,　矢野聖二.　膵胆道疾患における胆汁及び血漿中癌抑制型miRNAのメチル化異常に関する検討.　2021年4月　東京
9. 第25回日本がん分子標的治療学会　鈴木千晶,　柳村尚寛,　新井祥子,　福田康二,　西山明宏,　竹内伸司,　矢野聖二.　第二世代TRK阻害薬の耐性機構解明と耐性克服治療の探索.　2021年5月 Web
10. 第25回日本がん分子標的治療学会　柳村尚寛,　竹内伸司,　新井祥子,　福田康二,　西山明宏,　矢野聖二. ALK 融合遺伝子陽性肺癌における STAT3 阻害薬の併用によるアポトーシス抵抗性の克服.　2021年5月 Web
11. 第30回日本がん転移学会学術集会　南條成輝,　Azad Tej,　Bivona Trever,　Diehn Maximilian.　脳脊髄液腫瘍由来DNA（CSF-ｔDNA）を用いたEGFR変異肺がん中枢神経系転移における治療最適化. 2021年 7月 Web
12. 第30回日本がん転移学会学術集会　南條成輝,　Okimoto Ross,　矢野聖二,　Bivona Trever.　転移性EGFR変異肺がんにおいて併存するRBM10遺伝子変異によるEGFR-TKI阻害薬耐性. 2021年 7月 Web
13. 第30回日本がん転移学会学術集会（研究奨励賞受賞講演） 新井祥子,　竹内伸司,　福田康二,　西山明宏,　谷本　梓,　谷口寛和,　片山量平,　山本卓志,　矢野聖二.　EML4-ALK肺癌の髄膜癌腫症モデルにおけるamphiregulinに起因するアレクチニブ耐性の克服. 2021年 7月 Web
14. 第52回日本膵臓学会大会　大坪公士郎,　三宅邦夫,　山下　要,　矢野聖二.　 胆汁中癌抑制型miRNAのメチル化異常による各種膵胆道疾患の鑑別と血漿への応用.　2021年9月 東京
15. 第80回日本癌学会学術総会　Tanimoto A, Yano S.　Resistance to targeted therapy stratified with oncogenes or tumor suppressor genes.　2021年10月　横浜
16. 第62回日本肺癌学会学術集会　矢野聖二. 分子標的薬抵抗性・耐性の治療標的.　 2021年11月　横浜
17. 第62回日本肺癌学会学術集会　竹内伸司.　RET融合遺伝子及びKRAS変異陽性肺癌における分子標的薬の開発状況.　2021年11月　横浜Web
18. 第62回日本肺癌学会学術集会　南條成輝, Okimoto Ross, 矢野聖二, Bivona Trever. Deficiency of splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer. 2021年11月　横浜
19. 令和3年度北信がんプロ合同市民公開講座 矢野聖二.　北信がんプロ5年間のあゆみ.　2021年12月　富山
20. 令和3年度北信がんプロ合同市民公開講座　小谷　浩.　北信がんプロデータベースで北陸・信州のがんの特徴をあぶりだす！ 2021年12月　富山

**＜学会発表・国際＞**

1. AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics Tanimoto A. The impact of BCL2 expression on sensitivity to the novel Aurora kinase B inhibitor AZD2811 in small cell lung cancer.　2021年10月　Virtual Meeting
2. The 25th Congress of the Asian Pacific Society of Respirology（APSR）Nanjo S. Co-mutation in splicing factor with EGFR mutations limits sensitivity to EGFR-TKIs ～Why are EGFR-TKIs less effective against EGFR L858R?～　2021年11月　京都